ACGN — Aceragen Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- $3.20m
- $1.08m
- $4.86m
Idera Pharmaceuticals: Gains on positive data from bowel cancer drug study
Brief: Idera Pharmaceuticals Files For Resale Of Up To 6.1 Million Shares By Selling Stockholder
Brief: Idera Announces Preliminary Data From Illuminate-206 Trial For Treatment Of Micro-Satellite Stable Colorectal Cancer
U.S. RESEARCH ROUNDUP-Cambium Networks, Compass Diversified Holdings, Zendesk
Brief: Idera Pharmaceuticals Announces Final Clinical Safety And Efficacy Data From Illuminate-204 Trial In Advanced Melanoma
Brief: Idera Pharmaceuticals Reports Q4 Loss Per Share Of $1.76
Brief: Idera Pharmaceuticals Completes Enrollment In Illuminate-301, Its Registrational Trial Of Tilsotolimod In Combination With Ipilimumab In Patients With Anti-Pd-1 Refractory Advanced Melanoma
Brief: Idera Pharmaceuticals Says Co Entered Into A Securities Purchase Agreement
Brief: Idera Pharmaceuticals Reports Q3 Loss Per Share Of $0.39
Brief: Idera Pharmaceuticals Announces New U.S. Patent For Tilsotolimod Through September 2037
Brief: Idera Pharmaceuticals Announces Initiation Of Illuminate-206 Trial Evaluating Tilsotolimod In Combination With Nivolumab And Ipilimumab For Treatment Of Solid Tumors
U.S. STOCKS ON THE MOVE-Tyson Foods, Box Inc, American Eagle, Navistar
U.S. STOCKS ON THE MOVE-Starbucks, American Eagle, Tapestry, JetBlue
U.S. STOCKS ON THE MOVE-American Eagle, Tapestry, Top Ships, JetBlue Airways, Navistar
Idera Pharmaceuticals: Climbs on entering research partnership with AbbVie
Brief: Idera Pharma Announces Immuno-Oncology Clinical Research Collaboration With Abbvie
Brief: Idera Pharmaceuticals Reports Q2 Loss Per Share $0.39
Brief: Idera Pharmaceuticals Announces Appointments Of Elizabeth Tarka As Chief Medical Officer And John Kirby As Chief Financial Officer
Brief: Idera Pharmaceuticals Reports Q1 Loss Per Share $0.40